Qnexa Obesity

Qnexa Obesity

VIVUS announces that obese patients on Qnexa had a weight lost averaging 14.7%.

Read full details.

What Vivus says about the trial:

• The EQUATE trial demonstrated superior weight loss with both the full-dose and mid-dose of Qnexa, as compared to the individual components and placebo.
  
• Subjects treated with full-dose and mid-dose Qnexa had an average weight loss of 9.2% and 8.5% respectively, as compared to weight loss of 1.7% reported in the placebo group (ITT LOCF p<0.0001).
  
• Average weight loss was 19.8 pounds and 18.2 pounds in the treatment arms as compared to 3.3 pounds in the placebo group.
  
• Qnexa was well tolerated with no drug-related serious adverse events in the study.

Read more.

Time to get excited about real help for serious weight loss ?

• Remember this is not really new technology because Qnexa is a combination of phentermine and topamax.
• There are side affects - lots of them.
• Qnexa is not yet available. In fact it has yet been submitted for approval by FDA.